Esmolol
- 1 March 1995
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 28 (3) , 190-202
- https://doi.org/10.2165/00003088-199528030-00002
Abstract
Esmolol is an ultra short-acting intravenous cardioselective β-antagonist. It has an extremely short elimination half-life (mean: 9 minutes; range: 4 to 16 minutes) and a total body clearance [285...Keywords
This publication has 48 references indexed in Scilit:
- Effect of Hypothermia and Sampling Site on Blood Esmolol ConcentrationsThe Journal of Clinical Pharmacology, 1993
- Cardiovascular and antiarrhythmic effects of esmolol in childrenThe Journal of Pediatrics, 1991
- The Phenomenon and Rationale of Marked Dependence of Drug Concentration on Blood Sampling SiteClinical Pharmacokinetics, 1989
- The Phenomenon and Rationale of Marked Dependence of Drug Concentration on Blood Sampling SiteClinical Pharmacokinetics, 1989
- Pharmacokinetics of Esmolol in Hepatic DiseaseThe Journal of Clinical Pharmacology, 1987
- Hemodynamic Effects of Esmolol, an Ultrashort-acting Beta BlockerThe Journal of Clinical Pharmacology, 1987
- Esmolol-Digoxin Drug InteractionThe Journal of Clinical Pharmacology, 1987
- Effect of propranolol in postinfarction patients with mechanical or electrical complications.Circulation, 1984
- Pharmacokinetics of propranololJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a β-adrenoreceptor blockerAmerican Heart Journal, 1979